NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) Thursday
announced that the Committee for Medicinal Products for Human Use or CHMP of the
European Medicines Agency has recommended marketing authorization for its
Omicron JN.1-adapted monovalent COVID-19 vaccine for active immunization.

This drug is intended to prevent COVID-19 caused by SARS-CoV-2 in individuals 6
months of age and older. The adaptation is based on the World Health
Organization's Technical Advisory Group on COVID-19 Vaccine Composition and the
European Medicines Agency's Emergency Task Force.

The European Commission will review the CHMP's recommendation and will make a
final decision.

The CHMP's recommendation is based on the full body of previous clinical,
non-clinical, and real-world evidence supporting the safety and efficacy of the
COVID-19 vaccines by Pfizer and BioNTech.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX